Dexcel Pharma USA Expands Offerings with Zubsolv Acquisition
Dexcel Pharma USA has accomplished a significant milestone by successfully closing an Asset Purchase Agreement with Orexo AB. This deal grants Dexcel Pharma the U.S. rights to Zubsolv (buprenorphine and naloxone) sublingual tablets and the essential commercial infrastructure that accompanies it. This acquisition marks a pivotal step forward in the company’s journey, enhancing its capability to promote branded products effectively.
Strategic Growth in the U.S. Market
Doug Boothe, the CEO of Dexcel Pharma, expressed enthusiasm about this acquisition, stating, "Dexcel Pharma is excited to be adding the Zubsolv product and related commercial capabilities from Orexo into our expanding U.S. operations." This acquisition affords Dexcel Pharma the opportunity to leverage its proven sales and marketing platform to fuel strategic growth across the U.S. pharmaceutical market.
Enhancing Access to Vital Therapies
The acquisition of Zubsolv is not just a growth strategy but also a commitment to enhancing patient access to essential therapies for treating opioid use disorder. Dexcel Pharma aims to ensure that new and existing customers continue to benefit from Zubsolv's therapeutic properties. The ability to integrate this product into their portfolio aligns perfectly with their mission of improving patient outcomes.
Appreciation for Team Efforts
In light of this significant accomplishment, the company extended its gratitude to its dedicated employees and third-party advisors, particularly DLA Piper LLP (US), for their invaluable support throughout this transaction. Their hard work has facilitated a smooth transition and paved the way for future collaborations with stakeholders in the pharmaceuticals industry.
Focus on Quality and Innovation
Dexcel Pharma USA, as a subsidiary of Dexcel Pharma, continues to assert its position in the pharmaceuticals field. Known as the largest private pharmaceutical company in Israel, Dexcel Pharma boasts a comprehensive portfolio of branded and generic medications. Their state-of-the-art research and development facilities, combined with superior manufacturing capabilities, allow the company to deliver high-quality products consistently.
Future of Dexcel Pharma USA
Looking ahead, Dexcel Pharma USA is committed to further expanding its offerings and maximizing the impact of Zubsolv in the treatment landscape for opioid use disorder. By maintaining long-term partnerships and staying attuned to the evolving needs of the market, the company is poised to make significant strides in providing innovative therapeutic solutions.
Frequently Asked Questions
What is Zubsolv?
Zubsolv is a sublingual tablet that contains buprenorphine and naloxone, used in the treatment of opioid dependence.
Why did Dexcel Pharma acquire Zubsolv?
This acquisition allows Dexcel Pharma USA to enhance its product offerings and efficiently market therapeutic solutions for opioid use disorder.
How will this acquisition impact patients?
The integration of Zubsolv will improve patient access to essential treatment options for those dealing with opioid dependency.
Who is Dexcel Pharma's CEO?
The CEO of Dexcel Pharma is Doug Boothe, who has expressed excitement about the growth opportunities from this acquisition.
What distinguishes Dexcel Pharma USA in the pharmaceutical industry?
Dexcel Pharma USA leverages top-tier research, quality manufacturing, and a wide portfolio of pharmaceutical products, making it a leader in the sector.
